Mechanistic model for booster doses effectiveness in healthy, cancer and immunosuppressed patients infected with SARS-CoV-2 - Voutouri, Chrysovalantis; Hardin, C. Corey; Naranbhai, Vivek; Nikmaneshi, Mohammad R.; Khandekar, Melin J.; Gainor, Justin F; Stylianopoulos, Triantafyllos; Munn, Lance L.; Jain, Rakesh K. (medRxiv, 2022)
SARS-CoV-2 vaccines are effective at limiting disease severity, but effectiveness is lower among patients with cancer or immunosuppression. Effectiveness wanes with time and varies by vaccine type. Moreover, vaccines are based on the ancestral SARS-CoV-2 spike-protein that emerging variants may evade. Here, we describe a mechanistic mathematical model for vaccination-induced immunity, validate it with available clinical data, and predict vaccine effectiveness for varied vaccine platforms in the setting of variants with ability to escape immunity, increased virulence, or enhanced transmissibility. We further account for concurrent cancer or underlying immunosuppression. The model confirms enhanced immunogenicity following booster vaccination in immunosuppressed patients but predicts at least one more booster dose is required for these individuals to maintain protection. We further studied the impact of variants on immunosuppressed individuals as a function of the interval between multiple booster doses. Our model is useful for planning future vaccinations, and tailoring strategies to risk groups.Significance Statement Current SARS-CoV-2 vaccines are effective at preventing COVID-19 or limiting disease severity in healthy individuals, but effectiveness is lower among patients with cancer or immunosuppression. Here, we address the need for predictions of vaccine effectiveness over time by building on our mathematical framework to account for vaccination-induced immunity. A booster dose of both mRNA vaccines can induce a robust enhancement of both antibody levels and numbers of pertinent types of adaptive immune cells, which is predicted to provide sufficient protection for more than one year in healthy patients. However, our model suggests that for immunosuppressed people or patients with cancer receiving an immunosuppressive treatment, the booster effect may wane, and perhaps could be considered on a more frequent basis.Competing Interest StatementCompeting Interest Statement: J.F.G. has served as a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech/Roche, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, Moderna, Mirati, AstraZeneca, Pfizer, Novartis, iTeos, Nuvalent, Karyopharm, Beigene, Silverback Therapeutics, Merck, and GlydeBio; research support from Novartis, Genentech/Roche, and Ariad/Takeda; institutional research support from Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an employee with equity at Ironwood Pharmaceuticals. L.L.M. owns equity in Bayer AG and is a consultant for SimBiosys. R.K.J. received consultant fees from Elpis, Innocoll, SPARC, SynDevRx; owns equity in Accurius, Enlight, Ophthotech, SynDevRx; and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund; and received a grant from Boehringer Ingelheim. Neither any reagent nor any funding from these organizations was used in this study. Other co-authors have no conflict of interests to declare.Funding StatementRakesh Jains research is supported by R01-CA259253 R01-CA208205 R01-NS118929 U01-CA261842 and U01-CA 224348 Outstanding Investigator Award R35-CA197743 and grants from the National Foundation for Cancer Research Jane's Trust Foundation American Medical Research Foundation and Harvard Ludwig Cancer Center. Lance Munn's research is supported by R01-CA2044949. Triantafyllos Stylianopoulos's research is supported by the European Research Council ERC-2019-CoG-863955. Chrysovalantis Voutouri is supported by Marie Skłodowska Curie Actions Individual Fellowship Global Horizon 2020 MSCA-IF-GF-2020-101028945. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham Institutional Review Board of Massachusetts General Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability. All data supporting the findings of this study are available in the paper and the Supplementary Information. Code availability. The COMSOL code will become available in Zenodo upon acceptance of the manuscript.